Furthermore, arming with BiAbs creates artificial cytotoxic T lymphocytes wherein TCR engagement via BiAb-bridge between the armed ATC and the antigen on the tumor cells induces release of significantly higher levels of IFN-γ, IL-2R, IL-12, CCL3, CCL4 and CXCL9, compared to unarmed ATC used as controls[19]. The gene discussed is CXCL9; the disease is neoplasm.